Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
To explain in laymens terms ............ every time you have an immune response .. your Immune system leaves a "signature"
so you have specific T cells that can be detected against the vaccine epitopes
if the T cells "expand" = mount an immune response ......... a signature cytokine is detected
Keytruda responders have "exhausted T cells" that are being turned on and maybe of low affinity
The GP100 epitope part of the vaccine will help them to .. as it washes IFyn over them because its CD4 helper T cell
you then have the TPR2 CD8's of High Avidity ... supporting the low affinity exhausted T cells ..
the reason why you have poor t cells is because the cancer "escaped the immune response"
Keytruda only works on T cells ...
the "bar" set at 14% or 30% ... is statistics ... indeed i posted the important data from the trial ...
Its not just the 30% res-ponders .. its the "CR" responders and then its the time in treatment of that "CR" does SCIB1 give a second kick to patients that would have responded anyway to keytruda ... so a "keytruda partial responder becomes " "complete response " ... you have to look at the data that could be produced in far more detail .. because they can track every patient via blood work and scans
Inanaco,
Genexine already have a deal with Merck and that's the difference! Their trial is a phase I/II - the aim of which is simply to establish whether the combination is safe and merits further development. The bar in HPV cancer is also set much lower as from memory only about 10% to 15% of patients respond to Keytruda alone.
The purpose of the SCIB1 combination is all of the above but also the results must be good enough to attract an offer from big pharma. Scancell already have great data in small numbers and big pharma wasn't interested. On top of that other combinations are moving the bar ever higher, Scancell's results don't have to simply be superior to Keytruda as a monotherapy but they're also completing with other PD-1 combinations.
I hope I'm wrong but I was so pleased when Scancell announced they would be running an 85 patient randomised study for SCIB1 in melanoma and so bitterly disappointed when it was scaled back to a single arm, uncontrolled study. That's why SCIB2 trial is so important and am looking forward to hearing how CRUK are doing on that front.
You could place HLA restrictions on the second Immunobody ... treating only the patients SCIB1 left behind .. Scancell owns the technology .. for both versions
on the 45% patient criteria .... allowing the min of 3 years to bring the mark 2 into the clinic I appreciate that is under a different Immunobody patent, plus at least 1 year in a phase 1 ... the mark 1 version is already 4 years ahead .. with predicted sales even of £500m would generate a £2b cash bonanza for £50m /70m expenditure . any deal with SCIB1 could include options on Mark 2
Red Herring
Bermuda
despite the fact that genexine and merck only have 28 patients with a 10 lead in ? how is it Merck will pay only for small numbers ?
scancell already has 35 "immune responses" which is what this is all about ..
Wild,
The issue isn't anything to do with how easy it would be for AN Other to copy SCIB1 - it's whether big pharma would be prepared to pay for a product with such a short patent life, even with market exclusivity in the US.
If you want my honest opinion (I know you probably don't lol) but I think Knowlesi is probably right about SCIB1 in it's current form. I can't ever see it getting to market or anybody paying to license it. That's mainly because as Inanaco alluded to yesterday, SCIB1+ is sitting there waiting to be developed and I can't see anybody paying to run a large randomised study with a vaccine that only works in 45% of the population when another is available that covers 90%.
Moreover, for reasons discussed before, I'm not convinced a trial in 25 patients will be enough to persuade big pharma to make a move for SCIB1 and IMO the future of ImmunoBody lies with SCIB2.
Obvs. just my opinion.
https://www.lexology.com/library/detail.aspx?g=f9dda657-ab4d-4496-a891-772f48b8cc3d
you need to add 5 year to to the patent date ... even if we had used up the 5 years before approval, you would still get a further 7
299 quid?! Ridiculous! Lidl are doing one for 149 next week, with a pack of needles and six free mice included.
TOP work Knowie! Now everyone is debating patents - it worked ;)
Oh No ........... !! Black&decker have just launched a cordless electroporation device for £299 at B and Q hot off the press says nowless ...
Surely we have to wait for the upcoming trial. What if it was incredibly successful ? Would there be a stage 3 trial ?
Berm .. how easy do you think it would be to make a copy of scib1 and deliver it so as to satisfy the authorities that your copy is the ‘same’ ?
This is certainly not as simple a process as replicating things like fixed small molecules in my opinion !?
Take care ..